Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

International Randomized Study of Transarterial Chemoembolization (TACE) Versus Stereotactic Body Radiotherapy (SBRT) / Stereotactic Ablative Radiotherapy (SABR) for Residual or Recurrent Hepatocellular Carcinoma After Initial TACE

NCT02762266 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.

NCT NCT02762266
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02762266 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
International Randomized Study of Transarterial Chemoembolization (TACE) Versus Stereotactic Body Radiotherapy (SBRT) / Stereotactic Ablative Radiotherapy (SABR) for Residual or Recurrent Hepatocellular Carcinoma After Initial TACE
Lead sponsor
Stanford University
Phase
Phase 3
Overall status
Terminated
Start date
February 27, 2016
Completion date
December 31, 2022
Enrollment
13 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

child-pugh class a, child-pugh class b, recurrent hepatocellular carcinoma